GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Operating Margin %

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Operating Margin % : -52.38% (As of Sep. 2018)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Keryx Biopharmaceuticals's Operating Income for the three months ended in Sep. 2018 was $-14.69 Mil. Keryx Biopharmaceuticals's Revenue for the three months ended in Sep. 2018 was $28.04 Mil. Therefore, Keryx Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2018 was -52.38%.

The historical rank and industry rank for Keryx Biopharmaceuticals's Operating Margin % or its related term are showing as below:

KERX' s Operating Margin % Range Over the Past 10 Years
Min: -3978.25   Med: -623.8   Max: 38.97
Current: -93.71


KERX's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -168.78 vs KERX: -93.71

Keryx Biopharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Keryx Biopharmaceuticals's Operating Income for the three months ended in Sep. 2018 was $-14.69 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2018 was $-88.60 Mil.


Keryx Biopharmaceuticals Operating Margin % Historical Data

The historical data trend for Keryx Biopharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Operating Margin % Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -672.61 -1,027.52 -811.90 -383.84 -167.69

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -158.17 -166.00 -104.60 -78.26 -52.38

Competitive Comparison of Keryx Biopharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Operating Margin % falls into.



Keryx Biopharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Keryx Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2017 is calculated as

Operating Margin %=Operating Income (A: Dec. 2017 ) / Revenue (A: Dec. 2017 )
=-101.691 / 60.641
=-167.69 %

Keryx Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2018 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2018 ) / Revenue (Q: Sep. 2018 )
=-14.686 / 28.036
=-52.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keryx Biopharmaceuticals  (NAS:KERX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Keryx Biopharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Headlines

From GuruFocus

Keryx Pharmaceuticals Announces Upcoming Investor Presentations

By Marketwired Marketwired 05-30-2018